Show simple item record

dc.contributor.authorBall, Heidi
dc.date.accessioned2022-07-05T15:52:53Z
dc.date.available2022-07-05T15:52:53Z
dc.identifier.citationLeech, S. C., Ewan, P. W., Skypala, I. J., Brathwaite, N., Erlewyn-Lajeunesse, M., Heath, S., Ball, H., James, P., Murphy, K., & Clark, A. T. (2021). BSACI 2021 guideline for the management of egg allergy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 51(10), 1262–1278.en_US
dc.identifier.other10.1111/cea.14009
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15633
dc.description.abstractThis guideline advises on the management of patients with egg allergy. Most commonly egg allergy presents in infancy, with a prevalence of approximately 2% in children and 0.1% in adults. A clear clinical history will confirm the diagnosis in most cases. Investigation by measuring egg-specific IgE (by skin prick testing or specific IgE assay) is useful in moderate-severe cases or where there is diagnostic uncertainty. Following an acute allergic reaction, egg avoidance advice should be provided. Egg allergy usually resolves, and reintroduction can be achieved at home if reactions have been mild and there is no asthma. Patients with a history of severe reactions or asthma should have reintroduction guided by a specialist. All children with egg allergy should receive the MMR vaccine. Most adults and children with egg allergy can receive the influenza vaccine in primary care, unless they have had anaphylaxis to egg requiring intensive care support. Yellow Fever vaccines should only be considered in egg-allergic patients under the guidance of an allergy specialist. This guideline was prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) and is intended for allergists and others with a special interest in allergy. The recommendations are evidence based. Where evidence was lacking, consensus was reached by the panel of specialists on the committee. The document encompasses epidemiology, risk factors, diagnosis, treatment, prognosis and co-morbid associations.
dc.description.urihttps://onlinelibrary.wiley.com/doi/10.1111/cea.14009en_US
dc.subjectEgg hypersensitivityen_US
dc.subjectAnaphylaxisen_US
dc.subjectChilden_US
dc.subjectSkin testsen_US
dc.subjectVaccinesen_US
dc.subjectAllergyen_US
dc.subjectEggen_US
dc.titleBSACI 2021 guideline for the management of egg allergyen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1111/cea.14009en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2021-10
html.description.abstractThis guideline advises on the management of patients with egg allergy. Most commonly egg allergy presents in infancy, with a prevalence of approximately 2% in children and 0.1% in adults. A clear clinical history will confirm the diagnosis in most cases. Investigation by measuring egg-specific IgE (by skin prick testing or specific IgE assay) is useful in moderate-severe cases or where there is diagnostic uncertainty. Following an acute allergic reaction, egg avoidance advice should be provided. Egg allergy usually resolves, and reintroduction can be achieved at home if reactions have been mild and there is no asthma. Patients with a history of severe reactions or asthma should have reintroduction guided by a specialist. All children with egg allergy should receive the MMR vaccine. Most adults and children with egg allergy can receive the influenza vaccine in primary care, unless they have had anaphylaxis to egg requiring intensive care support. Yellow Fever vaccines should only be considered in egg-allergic patients under the guidance of an allergy specialist. This guideline was prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) and is intended for allergists and others with a special interest in allergy. The recommendations are evidence based. Where evidence was lacking, consensus was reached by the panel of specialists on the committee. The document encompasses epidemiology, risk factors, diagnosis, treatment, prognosis and co-morbid associations.en_US


This item appears in the following Collection(s)

Show simple item record